The Prescrire Awards for 2011
The 2011 Prescrire Awards: granted in total independence by Prescrire's Editorial Staff
Prescrire's review of new drugs and new indications in 2011
Prescrire's ratings of new products and indications over the last 10 years
| Prescrire's ratings of new products and indications over the last 10 years (a) |
PRESCRIRE'S RATING
|
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
| Bravo |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
| A real advance |
4 |
4 |
0 |
1 |
1 |
2 |
0 |
0 |
1 |
0 |
| Offers an advantage |
9 |
5 |
6 |
4 |
8 |
14 |
6 |
3 |
3 |
3 (c) |
| Possibly helpful |
18 |
23 |
12 |
20 |
31 |
27 |
25 |
14 |
22 |
13 |
Nothing new
|
35 |
34 |
41 |
38 |
69 |
79 |
57 |
62 |
49 |
53 |
Not acceptable
|
6 (b) |
7 (b) |
7 |
19 |
17 |
15 |
23 |
19 |
19 |
16 (d) |
Judgement reserved
|
0 |
6 |
4 |
2 |
8 |
3 |
9 |
6 |
3 |
7 (e) |
| Total |
72 |
79 |
4 |
84 |
135 |
141 |
120 |
104 |
97 |
92 |
| |
| Notes : |
| a - For reasons of space, this table only shows the results for the last 10 years. The previous years’ results (1981 to 2001) can be found in Prescrire Int n°58. This table shows new products (other than generics copies) and new indications proposed by drug companies to physicians and pharmacists, for use in hospitals and/or the community; and, from 2005 onwards, line extensions (new dose strengths, new form/presentations of existing drugs) and products for self-medication, rated in our French edition la revue Prescrire. A given product is counted several times if it was rated differently in its different indications. |
| b - Including two jointly marketed products. |
|
c - The drugs were:
- collagenase clostridium histolyticum in Dupuytren’s contracture (Prescrire Int n° 122);
- mesalazine in ulcerative colitis and Crohn’s disease in children (Prescrire Int n° 119);
- tocofersolan in vitamin E deficiency (Rev Prescrire n° 333).
|
|
d - The drugs were:
- aciclovir + hydrocortisone in herpes labialis (Prescrire Int n° 119);
- bendamustine in second line therapy of indolent non-Hodgkin's lymphomas and multiple myeloma (Rev Prescrire n° 338);
- bleomycin in malignant pleural effusion (Prescrire Int n° 122);
- denosumab in postmenopausal osteoporosis (Prescrire Int n° 117);
- denosumab in prostate cancer related bone loss (Rev Prescrire n° 329);
- docetaxel in adjuvant therapy for breast cancer (Prescrire Int n° 117);
- erlotinib in maintenance therapy of non-small cell lung cancer (Prescrire Int n° 120);
- exenatide in type 2 diabetes in combination with glitazones (Rev Prescrire n° 328);
- fampridine in multiple sclerosis and walking disorder (Rev Prescrire n° 337);
- lanthane with more follow-up in dialysis patients with chronic kidney failure (Rev Prescrire n° 329);
- lanthane in non-dialysis patients with chronic kidney failure (Rev Prescrire n° 329);
- methotrexate 10 mg, a strong dosage in rhumatology (Rev Prescrire n° 331);
- moxifloxacin in community acquired pneumonia and skin infections (Rev Prescrire n° 327 + 328);
- omalizumab, a weak dosage in severe persistent asthma (Prescrire Int n° 121);
- prucalopride in women with chronic constipation (Prescrire Int n° 116);
- botulinum toxin type A for migraine (Prescrire Int n° 122).
|
e - The drugs include:
- abatacept in juvenile idiopathic arthritis (Rev Prescrire n° 328);
- alglucosidase alfa in late Pompe disease (Rev Prescrire n° 336);
- bevacizumab off-label in age-related macular oedema (Rev Prescrire n° 331);
- cabazitaxel in advanced prostate cancer (Prescrire Int n° 123);
- quetiapine (Xeroquel LP°) in prevention of depression in bipolar disorder (Prescrire Int n° 121);
- rituximab in maintenance treatment of follicular lymphoma (Rev Prescrire n° 338);
- sunitinib in pancreatic neuroendocrine tumours (Rev Prescrire n° 337).
|
| ©Prescrire April 2012 |
| "New drugs and new indications in 2011. France is better focused on patients' interests after the Mediator° scandal, but stagnation elsewhere" Prescrire Int 2012; 21 (126): 106-110. (pdf, free) |
| > Return to Prescrire's review of new drugs and new indications in 2011 |
